European Commission

September 14, 2018

Darzalex Combination Approved in Europe for Some Newly Diagnosed Multiple Myeloma Patients

News

The European Commission has approved the anti-CD38 antibody Darzalex (daratumumab), in combination with standard therapy, for newly diagnosed multiple myeloma patients who cannot receive a stem cell transplant. The approval is ... Read more

December 18, 2017

CellProtect Receives EU Orphan Drug Status for Treatment of Multiple Myeloma

News

The European Commission has granted orphan drug status to CellProtect as a treatment for multiple myeloma, according to the investigational therapy’s developer, CellProtect Nordic Pharmaceuticals. Using patients’ own blood ... Read more

June 7, 2016June 7, 2016

European Commission Approves Janssen’s Multiple Myeloma Treatment Darzalex (Daratumumab)

News

The European Commission (EC) has granted provisional approval to Janssen’s Darzalex (daratumumab) as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines ... Read more

May 13, 2016May 13, 2016

BMS, AbbVie Announce EC Approval of Empliciti For Multiple Myeloma

News

Bristol-Myers Squibb (BMS) Company and AbbVie have announced that the European Commission (EC) has approved Empliciti™ (elotuzumab) for the treatment of multiple myeloma in combination with Revlimid™ (lenalidomide) and dexamethasone ... Read more